← All trials
NCT04789616
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 9, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CalgaryLead sponsor
- Dalhousie UniversityCollaborator
- Memorial University of NewfoundlandCollaborator
- University of Western OntarioCollaborator
- Riverview Health Centre FoundationCollaborator
- University of TorontoCollaborator
- Adelson Medical Research FoundationCollaborator
- University of TorontoCollaborator
- University of British ColumbiaCollaborator
- University of CalgaryOverall official - principal investigator
- University of California, Los AngelesStudy chair
- University of California, Los AngelesCollaborator
- University of California, Los AngelesOfficial
- University of CalgaryOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.